Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.86 and traded as low as $2.72. Cryo-Cell International shares last traded at $2.97, with a volume of 14,239 shares.

Cryo-Cell International Stock Down 4.2%

The company’s fifty day moving average is $3.30 and its two-hundred day moving average is $3.86. The firm has a market capitalization of $23.94 million, a price-to-earnings ratio of -9.58 and a beta of 0.55.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.47) earnings per share (EPS) for the quarter. The business had revenue of $7.84 million for the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent quarter. 10.44% of the stock is currently owned by institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.